CD274 and neoplasm: Preliminary observations of patients with recurrent cancers indicate that clinical responses to immune checkpoint blockers are associated with elevated tumor levels of immune inhibitory signals, such as PD-L1, cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and with increased numbers of TILs.